The company
Puma Biotechnology Inc
PBYI · Nasdaq
PBYI stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 21.8% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 52 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $4.1M
- Officials’ trades on record
- 7
- Institutions holding
- 157 (+9)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
7 disclosed lines: House 7, Senate 0, executive 0; 2 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donna E. Shalala House: U.S. House ClerkFL27 | sold | $1k–$15k | 15 May 2019filed 27 Apr 2020 |
| Donna E. Shalala House: U.S. House ClerkFL27 | bought | $1k–$15k | 23 Jan 2019filed 27 Apr 2020 |
| Nick J. Rahall II House: U.S. House ClerkWV03 | sold | $1k–$15k | 26 Sep 2014filed 13 Oct 2014 |
| Nick J. Rahall II House: U.S. House ClerkWV03 | bought | $1k–$15k | 10 Sep 2014filed 13 Oct 2014 |
| Nick J. Rahall II House: U.S. House ClerkWV03 | bought | $1k–$15k | 30 Jul 2014filed 14 Aug 2014 |
| Nick J. Rahall II House: U.S. House ClerkWV03 | bought | $15k–$50k | 24 Jul 2014filed 14 Aug 2014 |
| Nick J. Rahall II House: U.S. House ClerkWV03 | sold | $15k–$50k | 23 Jul 2014filed 14 Aug 2014 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Alessandra CesanoDirector | sold | 62,150at $9.12 | 14 Sep 2026filed 16 Sep 2026 |
| Troy Edward WilsonDirector | sold | 5,000at $9.10 | 14 Sep 2026filed 16 Sep 2026 |
| Maximo F. NouguesChief Financial Officer | sold | 9,386at $8.26 | 6 Jul 2026filed 8 Jul 2026 |
| Douglas M. HuntOfficer | sold | 8,460at $8.26 | 6 Jul 2026filed 8 Jul 2026 |
| Alan H. AuerbachPresident and CEO | sold | 44,058at $8.26 | 6 Jul 2026filed 8 Jul 2026 |
| Allison DorvalDirector | sold | 11,610at $7.20 | 12 Jun 2026filed 15 Jun 2026 |
| Jay M. MoyesDirector | sold | 22,000at $7.22 | 12 Jun 2026filed 15 Jun 2026 |
| Adrian SenderowiczDirector | sold | 27,000at $7.20 | 12 Jun 2026filed 15 Jun 2026 |
| Brian M. StuglikDirector | sold | 8,100at $7.20 | 12 Jun 2026filed 15 Jun 2026 |
| Troy Edward WilsonDirector | sold | 10,800at $7.20 | 12 Jun 2026filed 15 Jun 2026 |
| Maximo F. NouguesChief Financial Officer | sold | 6,405at $5.88 | 7 Jan 2026filed 8 Jan 2026 |
| Douglas M. HuntOfficer | sold | 5,014at $5.88 | 7 Jan 2026filed 8 Jan 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| ACORN CAPITAL ADVISORS, LLCunchanged · filed 14 Aug 2026 | 4,131,299$33.5M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,804,736$30.9M | +205,784+5.7% |
| AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 2026 | 2,319,996$18.8M | +403,650+21.1% |
| RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026 | 1,836,213$14.9M | -106,200−5.5% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,835,643$14.9M | +17,962+1.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,825,599$14.8M | +90,950+5.2% |
| DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026 | 1,518,014$12.3M | +81,908+5.7% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 1,339,405$10.9M | +322,063+31.7% |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLCreduced · filed 13 Aug 2026 | 1,123,783$9.1M | -14,386−1.3% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 952,165$7.7M | +34,575+3.8% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.